Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391396 | 1.00 | TDP1 (0.45) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| Alcohol SCHEMBL27653568 | 0.89 | MAPT (0.41) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| SCHEMBL110092 | 0.83 | MAPT (0.47) | TDP1TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL29677457 | 0.83 | MAPT (0.47) | TDP1TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL27993405 | 0.82 | MAPT (0.38) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28178631 | 0.82 | MAPT (0.46) | TDP1TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL7006193 | 0.81 | CTSB (0.43) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| SCHEMBL2034272 | 0.79 | TDP1 (0.42) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| SCHEMBL1582439 | 0.79 | TDP1 (0.42) | TDP1TSHRALDH1A1MAPTCYP3A4 | |
| SCHEMBL539616 | 0.79 | NOS3 (0.48) | TDP1TSHRALDH1A1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104817494-B | A kind of method of one pot process flupirtine maleate | 江苏海岸药业有限公司 | 2017-09-29 | — | — | CN | claimed |
| CN-104817494-A | Method for synthesizing flupirtine maleate by use of one-pot process | JIANGSU COAST PHARMACEUTICAL CO LTD | 2015-08-05 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025109475-A1 | SHP-1 AGONISTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-114957107-B | Method for continuously synthesizing 2, 6-diamino-3, 5-dinitropyridine by using micro-channel | 华东理工大学 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-117924278-A | Diamine monomer, polyimide polymer, aromatic polyamide polymer, and preparation method and application thereof | 四川大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-114957107-A | Method for continuously synthesizing 2, 6-diamino-3, 5-dinitropyridine by micro-channel | 华东理工大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-105315199-B | N-pyridine aryloxy phenoxy carboxylic acid derivative and preparation method and application thereof | 湖南化工研究院有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10829511-B1 | Molecular recognition systems with pyrimidine analog pairing | BENNER STEVEN A (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2020120576-A1 | p38α AUTOPHOSPHORYLATION INHIBITORS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2020-06-18 | — | — | WO | disclosed |
| US-5157026-A | Oxo-purines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5102880-A | Biphenyl imidazotriazine derivatives; Hypotensive and cardiotonic agents | MERCK & CO., INC. (US) | 1992-04-07 | — | — | US | disclosed |
| CN-1048546-A | Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine | MERCK & CO INC (US) | 1991-01-16 | — | — | CN | disclosed |
| EP-0257399-B1 | HAIR DYEING COMPOSITION | Beratungslabor für die kosmetische und pharmazeutische Industrie Dipl.-Ing. Karlheinz Schrader (DE) | 1991-01-02 | — | — | EP | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0257399-A2 | Hair dyeing composition | Beratungslabor für die kosmetische und pharmazeutische Industrie Dipl.-Ing. Karlheinz Schrader (DE) | 1988-03-02 | — | — | EP | disclosed |
| EP-0137524-B1 | HAIR DYEING COMPOSITIONS | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1988-01-20 | — | — | EP | disclosed |
| EP-0137524-A1 | Hair dyeing compositions | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1985-04-17 | — | — | EP | disclosed |
| US-4068085-A | YELLOW AND RED ON POLYESTERS AND ACRYLICS | CIBA-GEIGY CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829511-B1 | Molecular recognition systems with pyrimidine analog pairing | DPYD, DTYMK, TYMS | TDP1 253/4885TSHR 2708/4885ALDH1A1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.